
|Videos|January 20, 2014
The Black Swan Research Initiative® and a Paradigm Shift in the Treatment of Multiple Myeloma
Author(s)Brian G.M. Durie, MD
Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses the Black Swan Research Initiative® of the IMF and a paradigm shift in the treatment of multiple myeloma.
Advertisement
Clinical Pearls
Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses the Black Swan Research Initiative® of the IMF and a paradigm shift in the treatment of multiple myeloma.
- Many investigators are interested in the Black Swan Research Initiative to study minimal residual disease (MRD) or to study treatments that could achieve MRD-Zeroâ„¢
- Durie believes the time is right to not just compare treatments for multiple myeloma but to see if the disease is curable
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































